Prelude Capital Management, LLC Solid Biosciences Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$2.82 - $12.9 $33,318 - $152,413	-11,815 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.33 - $11.64 $51,158 - $137,526	11,815 New	11,815 $122,000
Q4 2018 Feb 14, 2019	SELL	$21.32 - $46.34 $19,188 - $41,706	-900 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$36.35 - $51.7 $21,810 - $31,020	-600 Reduced 40.0%	900 $42,000
Q2 2018 Aug 14, 2018	SELL	$7.33 - $43.15 $25,508 - $150,162	-3,480 Reduced 69.88%	1,500 $53,000
Q1 2018 May 15, 2018	BUY	$7.19 - $33.17 $35,806 - $165,186	4,980 New	4,980 $37,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $55.7M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.